Q5125 HCPCS code: Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
Q5125 is the HCPCS Level II code for injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram. In 2024 Medicare paid an average of $0.38 per service for Q5125 across 8,044,673 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 1800 per day on outpatient hospital claims. Medicare volume rose 159% from 2023 to 2024 (3,106,095 to 8,044,673 services). In 2024, about 1,310 clinicians billed Medicare for Q5125 for 2,677 beneficiaries; Florida, Texas, California accounted for 40% of services.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2022-10-01 |
| Last action effective | 2022-10-01 |
Who bills Q5125 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,310 |
| Medicare beneficiaries | 2,677 |
| States with claims | 32 |
| Share of services in top 3 states (Florida, Texas, California) | 40% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for Q5125, 2023–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 3,106,095 | 1,147 | $0.55 | $0.44 |
| 2024 | 8,044,673 | 2,677 | $0.48 | $0.38 |
States with the most Q5125 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 1,108,440 | $0.38 |
| Texas | 1,093,320 | $0.37 |
| California | 970,850 | $0.38 |
| Arkansas | 617,520 | $0.37 |
| Washington | 588,000 | $0.37 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 1800 | Prescribing Information |
| practitioner claims | 1800 | Prescribing Information |
Medicare policy articles for this code
- A56748: Billing and Coding: White Cell Colony Stimulating Factors (Palmetto GBA (MAC - Part A, MAC - Part B))
Covered diagnoses (1,265 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| B20 | Human immunodeficiency virus [HIV] disease | 1 |
| C00.0 | Malignant neoplasm of external upper lip | 1 |
| C00.1 | Malignant neoplasm of external lower lip | 1 |
| C00.2 | Malignant neoplasm of external lip, unspecified | 1 |
| C00.3 | Malignant neoplasm of upper lip, inner aspect | 1 |
| C00.4 | Malignant neoplasm of lower lip, inner aspect | 1 |
| C00.5 | Malignant neoplasm of lip, unspecified, inner aspect | 1 |
| C00.6 | Malignant neoplasm of commissure of lip, unspecified | 1 |
| C00.8 | Malignant neoplasm of overlapping sites of lip | 1 |
| C00.9 | Malignant neoplasm of lip, unspecified | 1 |
Showing 10 of 1,265. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for Q5125
- 2022-10-01: Q5125 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q5125?
Q5125 is the HCPCS Level II code for injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram. Short descriptor: "Inj, releuko 1 mcg".
How much does Medicare pay for Q5125?
In 2024, the average Medicare payment was $0.38 per service (average allowed $0.48).
Does Medicare cover Q5125?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for Q5125?
Medicare policy articles that cite Q5125 list 1,265 covered ICD-10-CM diagnosis codes across 1 article. The most cited include B20 (Human immunodeficiency virus [HIV] disease), C00.0 (Malignant neoplasm of external upper lip), C00.1 (Malignant neoplasm of external lower lip). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of Q5125 can be billed per day?
1800 on outpatient hospital claims; 1800 on practitioner claims (NCCI medically unlikely edits).
Related Q51 codes
- Q5100 — Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
- Q5101 — Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5102 — Injection, infliximab, biosimilar, 10 mg
- Q5103 — Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104 — Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5107 — Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Q5108 — Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5109 — Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
- Q5110 — Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111 — Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q5125
- Watch Q5125 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q5125
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.